TPD52L1

Summary

TPD52L1 (TPD52 like 1, HGNC:12006) is a protein-coding gene on chromosome 6q22.31, encoding Tumor protein D53 (Q16890).

This gene encodes a member of a family of proteins that contain coiled-coil domains and may form hetero- or homomers. The encoded protein is involved in cell proliferation and calcium signaling. It also interacts with the mitogen-activated protein kinase kinase kinase 5 (MAP3K5/ASK1) and positively regulates MAP3K5-induced apoptosis. Multiple alternatively spliced transcript variants have been observed.

Source: NCBI Gene 7164 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 36 total
• MANE Select transcript: NM_003287

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12006
Approved symbol	TPD52L1
Name	TPD52 like 1
Location	6q22.31
Locus type	gene with protein product
Status	Approved
Aliases	D53, hD53, TPD53
Ensembl gene	ENSG00000111907
Ensembl biotype	protein_coding
OMIM	604069
Entrez	7164

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 11 protein_coding, 4 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000304877, ENST00000368388, ENST00000368402, ENST00000392482, ENST00000392483, ENST00000524679, ENST00000527711, ENST00000528193, ENST00000530868, ENST00000532423, ENST00000532429, ENST00000532978, ENST00000534000, ENST00000534199, ENST00000534368, ENST00000571678, ENST00000576089

RefSeq mRNA: 8 — MANE Select: NM_003287 NM_001003395, NM_001003396, NM_001003397, NM_001292026, NM_001300994, NM_001318903, NM_001318907, NM_003287

CCDS: CCDS34527, CCDS34528, CCDS43502, CCDS5130, CCDS75513, CCDS75514, CCDS83122

Canonical transcript exons

ENST00000534000 — 7 exons

Exon	Start	End
ENSE00002194959	125153773	125153970
ENSE00003508867	125248282	125248383
ENSE00003600857	125229118	125229266
ENSE00003617631	125253717	125253755
ENSE00003675275	125257098	125257158
ENSE00003687765	125220078	125220193
ENSE00003692658	125262834	125264407

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 99.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 45.7837 / max 1387.3505, expressed in 1407 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
69644	23.7806	1219
69643	12.4820	1264
69645	7.3007	805
69647	0.5730	347
69648	0.5490	130
69646	0.4536	181
69656	0.2368	56
69657	0.1440	21
69654	0.1285	21
69653	0.0597	16

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	99.83	gold quality
right adrenal gland cortex	UBERON:0035827	99.40	gold quality
germinal epithelium of ovary	UBERON:0001304	99.36	gold quality
right adrenal gland	UBERON:0001233	99.34	gold quality
adrenal cortex	UBERON:0001235	99.17	gold quality
left adrenal gland	UBERON:0001234	99.16	gold quality
left adrenal gland cortex	UBERON:0035825	99.13	gold quality
cervix squamous epithelium	UBERON:0006922	99.08	gold quality
putamen	UBERON:0001874	98.87	gold quality
choroid plexus epithelium	UBERON:0003911	98.80	gold quality
pancreatic ductal cell	CL:0002079	98.78	gold quality
saliva-secreting gland	UBERON:0001044	98.69	gold quality
minor salivary gland	UBERON:0001830	98.57	gold quality
tongue squamous epithelium	UBERON:0006919	98.56	gold quality
mouth mucosa	UBERON:0003729	98.53	gold quality
squamous epithelium	UBERON:0006914	98.45	gold quality
esophagus squamous epithelium	UBERON:0006920	98.40	gold quality
lateral globus pallidus	UBERON:0002476	98.39	gold quality
nucleus accumbens	UBERON:0001882	98.38	gold quality
gingival epithelium	UBERON:0001949	98.34	gold quality
esophagus mucosa	UBERON:0002469	98.33	gold quality
gingiva	UBERON:0001828	98.22	gold quality
caudate nucleus	UBERON:0001873	98.22	gold quality
gluteal muscle	UBERON:0002000	97.93	gold quality
epithelium of esophagus	UBERON:0001976	97.91	gold quality
triceps brachii	UBERON:0001509	97.88	gold quality
lower esophagus mucosa	UBERON:0035834	97.81	gold quality
adrenal gland	UBERON:0002369	97.79	gold quality
penis	UBERON:0000989	97.78	gold quality
pharyngeal mucosa	UBERON:0000355	97.74	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 11.

Experiment	Marker?	Max mean expression
E-GEOD-180759	yes	1576.02
E-GEOD-98556	yes	560.56
E-HCAD-1	yes	241.81
E-HCAD-35	yes	80.49
E-GEOD-135922	yes	47.52
E-MTAB-10287	yes	47.27
E-HCAD-10	yes	22.55
E-GEOD-84465	yes	12.70
E-MTAB-7249	yes	11.29
E-MTAB-10137	yes	8.68
E-HCAD-30	no	880.00
E-ENAD-21	no	420.76
E-GEOD-124858	no	236.18
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

65 targeting TPD52L1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-8062	99.88	68.43	995
HSA-MIR-4671-3P	99.88	72.46	1045
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4524A-3P	99.72	66.85	2406

Literature-anchored findings (GeneRIF, showing 3)

• These results identify 14-3-3 proteins as partners for hD53, and alternative splicing as a mechanism for regulating 14-3-3 binding. (PMID:12963375)
• a member of the tumor protein D52 family involved in cell proliferation and calcium signaling, up-regulates the ASK1-induced apoptosis [D53L1] (PMID:14761963)
• The results indicate that tumor protein D52-like 1 genes are not ubiquitously expressed in leukemic bone marrow in children, and that RNA sample parameters may influence measures of gene expression more than commonly appreciated. (PMID:16620967)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tpd52l1	ENSDARG00000042548
mus_musculus	Tpd52l1	ENSMUSG00000000296
rattus_norvegicus	Tpd52l1	ENSRNOG00000021478
drosophila_melanogaster	CG5174	FBGN0034345
caenorhabditis_elegans		WBGENE00008745

Paralogs (3): TPD52 (ENSG00000076554), TPD52L2 (ENSG00000101150), TPD52L3 (ENSG00000170777)

Protein

Protein identifiers

Tumor protein D53 — Q16890 (reviewed: Q16890)

Alternative names: Tumor protein D52-like 1

All UniProt accessions (5): Q16890, E9PNK6, E9PNQ9, E9PPQ1, J3KNE7

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Forms a homodimer or heterodimer with other members of the family.

Similarity. Belongs to the TPD52 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q16890-1	1	yes
Q16890-2	2
Q16890-3	3
Q16890-4	4, +5hD53
Q16890-5	5

RefSeq proteins (8): NP_001003395, NP_001003396, NP_001003397, NP_001278955, NP_001287923, NP_001305832, NP_001305836, NP_003278* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007327	TPD52	Family

Pfam: PF04201

UniProt features (19 total): modified residue 8, splice variant 5, sequence conflict 2, chain 1, region of interest 1, sequence variant 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q16890-F1	65.60	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 174, 29, 86, 122, 131, 133, 146, 149

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-432722	Golgi Associated Vesicle Biogenesis

MSigDB gene sets: 216 (showing top): GOBP_REGULATION_OF_PHOSPHORYLATION, JAEGER_METASTASIS_DN, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, REACTOME_MEMBRANE_TRAFFICKING, MORF_RAD51L3, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_DN, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, KIM_RESPONSE_TO_TSA_AND_DECITABINE_UP, GOBP_APOPTOTIC_SIGNALING_PATHWAY

GO Biological Process (4): G2/M transition of mitotic cell cycle (GO:0000086), positive regulation of MAP kinase activity (GO:0043406), positive regulation of JNK cascade (GO:0046330), positive regulation of apoptotic signaling pathway (GO:2001235)

GO Molecular Function (3): identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
trans-Golgi Network Vesicle Budding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of MAPK cascade	2
cellular anatomical structure	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
MAP kinase activity	1
regulation of MAP kinase activity	1
positive regulation of protein serine/threonine kinase activity	1
JNK cascade	1
regulation of JNK cascade	1
positive regulation of signal transduction	1
positive regulation of apoptotic process	1
apoptotic signaling pathway	1
regulation of apoptotic signaling pathway	1
protein binding	1
identical protein binding	1
protein dimerization activity	1
binding	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

660 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TPD52L1	KDELR2	P33947	572
TPD52L1	LRIG3	Q6UXM1	567
TPD52L1	SLC34A2	O95436	511
TPD52L1	TMEM106B	Q9NUM4	506
TPD52L1	TPD52L2	O43399	498
TPD52L1	RET	P07949	481
TPD52L1	GOPC	Q9HD26	448
TPD52L1	LIMA1	Q9UHB6	447
TPD52L1	RRP8	O43159	414
TPD52L1	SLC6A17	Q9H1V8	393
TPD52L1	FAM135B	Q49AJ0	380
TPD52L1	BBX	Q8WY36	374
TPD52L1	ROS1	P08922	371
TPD52L1	TPM3	P06753	370
TPD52L1	SDC4	P31431	370

IntAct

56 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
YWHAB	TPD52L1	psi-mi:“MI:0407”(direct interaction)	0.690
YWHAB	TPD52L1	psi-mi:“MI:0915”(physical association)	0.690
TPD52	TPD52L1	psi-mi:“MI:0915”(physical association)	0.660
TPD52L1	TPD52	psi-mi:“MI:0915”(physical association)	0.660
YWHAG	BLTP3B	psi-mi:“MI:0914”(association)	0.640
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
YWHAB	BLTP3B	psi-mi:“MI:0914”(association)	0.610
YWHAZ	TPD52L1	psi-mi:“MI:0407”(direct interaction)	0.590
YWHAZ	TPD52L1	psi-mi:“MI:0915”(physical association)	0.590
YWHAH	BLTP3B	psi-mi:“MI:0914”(association)	0.570
TPD52L3	TPD52L2	psi-mi:“MI:0914”(association)	0.530
TPD52L1	TPD52L2	psi-mi:“MI:0914”(association)	0.530
AZIN2	OAZ2	psi-mi:“MI:0914”(association)	0.530
TPD52	TPD52L2	psi-mi:“MI:0914”(association)	0.530
AGMAT	DCX	psi-mi:“MI:0914”(association)	0.500
TPD52L1	DAPK1	psi-mi:“MI:0407”(direct interaction)	0.440
ABL2	TPD52L1	psi-mi:“MI:0915”(physical association)	0.370
TPD52L1	PAK6	psi-mi:“MI:0915”(physical association)	0.370
SFN	TPD52L1	psi-mi:“MI:0915”(physical association)	0.370
Tpd52	TPD52L1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (57): TPD52L1 (Affinity Capture-MS), ISYNA1 (Co-fractionation), TPD52L1 (Co-fractionation), TPD52L1 (Co-fractionation), UCHL3 (Co-fractionation), TPD52L1 (Affinity Capture-MS), TPD52L1 (Affinity Capture-MS), TPD52L1 (Affinity Capture-MS), TPD52L1 (Affinity Capture-RNA), TPD52L1 (Reconstituted Complex), TPD52L1 (Two-hybrid), GPR135 (Two-hybrid), HDAC1 (Two-hybrid), YAE1D1 (Two-hybrid), EIF3J (Two-hybrid)

ESM2 similar proteins: A5D7H2, A6QPI6, E1BWM5, F1N5S9, F1QH17, O35094, O43399, O43615, O54818, O60941, O70585, P55327, P58405, P84060, Q13033, Q16890, Q4R3C7, Q5BJS4, Q5R812, Q5RCT1, Q5SRX1, Q5VWJ9, Q5XGW6, Q5ZHP5, Q5ZJB7, Q5ZMQ0, Q62393, Q6GL11, Q6PCT3, Q6ZVM7, Q75Q41, Q8CE50, Q8IVP5, Q8K1Z0, Q8WUX9, Q95212, Q96IK1, Q96RU3, Q9CPQ3, Q9CYZ2

Diamond homologs: O43399, O54818, P55326, P55327, Q16890, Q5RCT1, Q62393, Q6PCT3, Q95212, Q96J77, Q9CYZ2, Q9I8F4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 42 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	138.4×	3e-10
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	122.1×	4e-10
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	122.1×	4e-10
Activation of BH3-only proteins	6	90.3×	2e-09
RHO GTPases activate PKNs	7	67.3×	4e-10
Intrinsic Pathway for Apoptosis	6	53.2×	4e-08
FOXO-mediated transcription	5	50.9×	1e-06
G2/M Checkpoints	8	32.6×	4e-09

GO biological processes:

GO term	Partners	Fold	FDR
intracellular protein localization	6	16.1×	6e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

36 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1579 predictions. Top by Δscore:

Variant	Effect	Δscore
6:125220064:A:AG	acceptor_gain	1.0000
6:125220069:T:A	acceptor_gain	1.0000
6:125220167:G:GT	donor_gain	1.0000
6:125220190:TCAG:T	donor_loss	1.0000
6:125220191:CAGGT:C	donor_loss	1.0000
6:125220193:GGTA:G	donor_loss	1.0000
6:125220194:G:C	donor_loss	1.0000
6:125220195:T:G	donor_loss	1.0000
6:125229108:C:CA	acceptor_gain	1.0000
6:125229114:GTA:G	acceptor_loss	1.0000
6:125229115:TAGC:T	acceptor_loss	1.0000
6:125229116:A:AG	acceptor_gain	1.0000
6:125229116:A:G	acceptor_loss	1.0000
6:125229117:G:GA	acceptor_gain	1.0000
6:125229117:G:T	acceptor_loss	1.0000
6:125229117:GCTA:G	acceptor_gain	1.0000
6:125229262:ACTGC:A	donor_gain	1.0000
6:125229263:CTGC:C	donor_gain	1.0000
6:125229264:TGC:T	donor_gain	1.0000
6:125229265:GC:G	donor_gain	1.0000
6:125229265:GCG:G	donor_gain	1.0000
6:125229266:CGT:C	donor_loss	1.0000
6:125229267:G:GG	donor_gain	1.0000
6:125229267:G:T	donor_loss	1.0000
6:125229268:TA:T	donor_loss	1.0000
6:125229269:AA:A	donor_loss	1.0000
6:125248280:A:AG	acceptor_gain	1.0000
6:125248281:G:GA	acceptor_gain	1.0000
6:125248281:GC:G	acceptor_gain	1.0000
6:125248281:GCTA:G	acceptor_gain	1.0000

AlphaMissense

1358 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:125248347:T:A	V117D	0.997
6:125229161:A:T	K60I	0.995
6:125248335:C:A	A113D	0.995
6:125248325:G:C	A110P	0.994
6:125248313:G:C	A106P	0.993
6:125229140:T:C	L53P	0.992
6:125229162:A:C	K60N	0.992
6:125229162:A:T	K60N	0.992
6:125248359:T:A	I121N	0.992
6:125257133:T:A	V154D	0.991
6:125257145:T:A	V158D	0.991
6:125248283:T:G	Y96D	0.990
6:125248314:C:A	A106E	0.988
6:125257111:T:C	F147L	0.986
6:125257113:C:A	F147L	0.986
6:125257113:C:G	F147L	0.986
6:125248334:G:C	A113P	0.985
6:125229119:T:C	L46P	0.984
6:125229143:G:C	R54P	0.984
6:125229173:T:C	L64P	0.983
6:125229241:T:A	W87R	0.983
6:125229241:T:C	W87R	0.983
6:125248359:T:G	I121S	0.983
6:125257098:G:C	R142S	0.983
6:125257098:G:T	R142S	0.983
6:125229157:G:C	A59P	0.982
6:125248326:C:A	A110E	0.982
6:125257112:T:C	F147S	0.981
6:125257121:T:C	F150S	0.981
6:125248355:G:C	A120P	0.977

dbSNP variants (sampled 300 via entrez): RS1000027106 (6:125230362 G>T), RS1000084038 (6:125229782 G>T), RS1000090963 (6:125224016 G>T), RS1000118764 (6:125222688 T>C), RS1000142717 (6:125180579 C>T), RS1000161050 (6:125206413 A>G), RS1000210680 (6:125155678 A>T), RS1000234134 (6:125164076 G>A), RS1000277374 (6:125249263 T>C), RS1000315547 (6:125235791 A>T), RS1000346003 (6:125200199 G>A), RS1000366031 (6:125152626 G>T), RS1000392768 (6:125243102 T>C), RS1000445352 (6:125158411 T>C,G), RS1000474960 (6:125158514 T>A,C)

Disease associations

OMIM: gene MIM:604069 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003542_126	Night sleep phenotypes	9.000000e-06
GCST012489_109	Heel bone mineral density x serum urate levels interaction	2.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

84 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects expression, affects cotreatment, increases expression, decreases expression	8
Valproic Acid	affects expression, affects cotreatment, increases expression	7
trichostatin A	affects cotreatment, increases expression	3
Cyclosporine	decreases expression, increases expression	3
Cadmium Chloride	increases expression, decreases expression	3
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Zoledronic Acid	decreases expression	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Acetaminophen	decreases expression, increases expression	2
Calcitriol	increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Progesterone	increases expression, decreases expression, affects cotreatment	2
Testosterone	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
testosterone enanthate	affects expression	1
daidzein	increases expression	1
methylmercuric chloride	increases expression	1
bisphenol A	decreases expression	1
glycidyl methacrylate	decreases expression	1
ferric ammonium citrate	increases expression, decreases reaction	1
beta-lapachone	decreases expression	1
afimoxifene	decreases reaction, increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
N-acetyl-4-benzoquinoneimine	affects response to substance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2JE	Abcam HeLa TPD52L1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.